Rozrolimupab

Drug Profile

Rozrolimupab

Alternative Names: Anti-RhD; Anti-Rhesus D; Anti-rhesus D immunoglobulin Gs; Anti-rhesus D polyclonal antibodies; Sym-001; Symphoglobulin-D

Latest Information Update: 13 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Symphogen
  • Class Immunoglobulins; Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action Rh-Hr blood group system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 01 May 2013 Rozrolimupab is considered to be outside Symphogen's oncology focus, and its further development is dependent on identification of a global partner
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IM)
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top